A larger effect on breast cancer prevention for women with benign breast disease was observed with aromatase inhibitors compared to tamoxifen, making this an attractive agent for postmenopausal women with proliferative disease. The gene discussed is CYP19A1; the disease is breast fibrocystic disease.